ArticleFrontiers in cellular and infection microbiology2026
Establishment of a blocking enzyme-linked immunosorbent assay based on tandem expression of dominant antigenic epitopes of the nucleocapsid protein from attenuated and virulent peste des petits ruminants virus.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peste des petits ruminants (PPR) is an acute, contagious disease caused by the Peste des Petits Ruminants virus (PPRV), mainly affecting small ruminants such as goats and sheep. PPR poses a serious threat to the healthy development of the livestock industry and wildlife safety. To develop a rapid method for detecting antibodies against the PPRV N protein, we analyzed the dominant antigenic epitopes of the N protein of virulent and attenuated PPRV strains using bioinformatics. The dominant antigenic epitopes of the N gene were linked in tandem via overlapping PCR and cloned into a prokaryotic expression system, yielding the recombinant plasmid, pET28a-PPRV-2N (encoding amino acids 1-250). Under optimized expression conditions, recombinant protein 2N was successfully produced after induction with isopropyl β-D-1-thiogalactopyranoside and purified. Using the purified recombinant PPRV-2N as the coating antigen in an enzyme-linked immunosorbent assay, the concentrations of the coating antigen and HRP-labeled monoclonal antibody against the PPRV N protein were optimized, resulting in the successful development of a blocking enzyme-linked immunosorbent assay (ELISA) for PPRV antibody detection. The new blocking ELISA detected positive serum at a minimum dilution of 1:10. The intra- and inter-assay coefficients of variation (CV) were both below 15%. No cross-reactivity was observed with sera positive for other important pathogens. When applied to 100 clinical serum samples, this method showed a 93% concordance with a commercial detection kit. The developed blocking ELISA method demonstrated good specificity, sensitivity, and repeatability, making it suitable for detecting PPRV antibodies. This technique supports the evaluation of PPRV vaccine-induced immune efficacy and aids in disease prevention and control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.